Literature DB >> 27590119

Risk Factors for Local Recurrence or Metastasis of Eyelid Sebaceous Gland Carcinoma After Wide Excision With Paraffin Section Control.

Yasuhiro Takahashi1, Emiko Takahashi2, Shunsuke Nakakura3, Yoshiyuki Kitaguchi1, Jacqueline Mupas-Uy1, Hirohiko Kakizaki4.   

Abstract

PURPOSE: To identify risk factors for local recurrence and metastasis of sebaceous gland carcinoma (SGC) after wide excision with paraffin section control.
DESIGN: Retrospective, observational case-control study.
METHODS: Setting: Single institution. PATIENT POPULATION: Thirty-four patients with SGC who had undergone excision with 5-mm surgical margins and paraffin section pathologic analysis. Observational Procedures: The following were considered potential risk factors for local recurrence/metastasis of SGC: patient's sex, patient's age, initial diagnosis at other clinics, topical treatments at other clinics, interval between appearance of symptoms and referral to our institution, tumor location, tumor origin, tumor presentation pattern, T category, tumor size, presence/or absence of pagetoid spread, tumor differentiation, mitosis grade, growth pattern. Logistic regression analysis was performed to identify the actual risk factors. MAIN OUTCOME MEASURES: Risk factors for local recurrence or metastasis of SGC after wide excision with paraffin section control.
RESULTS: Involvement of both upper and lower eyelids, topical treatments at other clinics, multicentric origin, diffuse pattern, stage T3a, large tumor size, and a nonlobular pattern significantly influenced local recurrence/metastasis (P < .050). Pagetoid spread tended to affect local recurrence/metastasis (P = .052). The other items did not significantly influence local recurrence/metastasis (P > .050).
CONCLUSIONS: This study identified risk factors for local recurrence or metastasis of SGC after wide excision with paraffin section pathologic analysis. The results of this study will be helpful to surgeons when planning additional management, such as map biopsy or adjuvant treatment.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27590119     DOI: 10.1016/j.ajo.2016.08.028

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  6 in total

Review 1.  Surgical Management of Periocular Cancers: High- and Low-Risk Features Drive Treatment.

Authors:  Richard C Allen
Journal:  Curr Oncol Rep       Date:  2017-09       Impact factor: 5.075

2.  Eyelid sebaceous carcinoma: Validation of the 8th edition of the American Joint Committee on cancer T staging system and the prognostic factors for local recurrence, nodal metastasis, and survival.

Authors:  Yun Hsia; Ching-Yuan Yeh; Yi-Hsuan Wei; Lily-Wei Chen; Shu-Lang Liao
Journal:  Eye (Lond)       Date:  2019-05-31       Impact factor: 3.775

Review 3.  Updates on the clinical diagnosis and management of ocular sebaceous carcinoma: a brief review of the literature.

Authors:  Yangfan Xu; Fang Li; Renbing Jia; Xianqun Fan
Journal:  Onco Targets Ther       Date:  2018-06-27       Impact factor: 4.147

4.  Outcome after treatment for sebaceous carcinoma: A multicenter study.

Authors:  Eva Huis In 't Veld; Ronald Keizer; Nicoline Post; Jeroen Versteeg; Robert Verdijk; Nicole Naus; Germaine Relyveld; Marianne Crijns; Myles Smith; Dirk Grünhagen; Marlies Wakkee; Dion Paridaens; Ioannis Zavrakidis; Antien Mooyaart; Alexander van Akkooi; Dirk Strauss; Cornelis Verhoef; Michel Wouters; Andrew Hayes; Winan van Houdt
Journal:  J Surg Oncol       Date:  2022-01-06       Impact factor: 2.885

5.  Nordic treatment practices survey and consensus for treatment of eyelid sebaceous carcinoma.

Authors:  Tiina Leivo; Johanna Sarmela; Maria Enckell-Aaltonen; Eva Dafgård Kopp; Caroline Schmitt; Peter B Toft; Haraldur Sigurdsson; Marita Uusitalo
Journal:  BMC Ophthalmol       Date:  2020-03-16       Impact factor: 2.209

6.  Management of recurrent sebaceous gland carcinoma.

Authors:  Lindsay A McGrath; Zanna I Currie; Hardeep Singh Mudhar; Jennifer H Y Tan; Sachin M Salvi
Journal:  Eye (Lond)       Date:  2020-01-02       Impact factor: 3.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.